05.05.25 -- Meeting The Demand For Cell & Gene Therapy Commercialization

Our analytical development and quality control teams ensure a robust focus on GMP analytics—critical for upholding the integrity and compliance of our clinical-phase productions.

Mario Kraft, Director of Process Development at AGC Biologics' Heidelberg facility, explains how platform processes optimize microbial, plasmid DNA, and mRNA production.

An integrated technology platform is designed to accelerate patient access to prescribed CGTs and deliver complete visibility to physicians and patient services teams.

Our team has decades of cell and gene therapy development experience and can help you achieve maximum return on investment for large pharma, biotech, and translational research.

Catalent’s UpTempo℠ AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current 18-20-month development timeline for drug product in half.

Ascend's EpyQ™ AAV production system offers a novel two plasmid alternative to triple transfection— comparative studies can be run to see what benefits your process most.

Choose from our different technology platforms or ask to customize a project. We’ll use our patented and proprietary technologies to ensure quality, accuracy, and fast turnaround times.

As a CDMO Partner for Life™, our goal is to advance your cell therapies from lab to commercial scale, leveraging our cell and gene therapy expertise and global cGMP network.

See how Forge’s dedicated 200,000 sq. ft. facility, proprietary technologies, and specialized services provide expert AAV manufacturing to empower developers from discovery to delivery.

Introducing Aldevron’s latest innovation. This enzymatic DNA manufacturing process produces linear DNA (linDNA) templates for in vitro transcription (IVT) of mRNA.